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Background: To compare the effect of combination anticoagulant and antiplatelet (AP) therapy with anticoagulation alone on stroke and bleeding 
risk in atrial fibrillation (AF) patients and examine predictors of clinically relevant bleeding. 
Methods: Post-hoc analysis of 4576 AF patients [mean (SD) age 70.1 (9.1) years, 66.5% men] enrolled in the AMADEUS trial, randomised to 
receive either subcutaneous idraparinux (2.5mg weekly, n=2283) or dose-adjusted vitamin K antagonists (VKAs) (INR 2.0-3.0, n=2293). 1031 
(22.5%) patients used concomitant AP therapy [idraparinux n=521 & VKAs n=510]. 
Results: 43 strokes [17 (0.6%) vs. 26 (2.7%)] and 553 clinically relevant bleeds [322 (11.2%) vs. 231 (27.6%)] occurred during follow-up 
on anticoagulation alone versus combination antithrombotic therapy, respectively. Clinically relevant bleeding was significantly associated with 
poor renal function, age ≥65, baseline VKA naivety, and concomitant AP therapy. Multivariate analyses [HR, 95% CI] revealed that age ≥65 years 
[1.45 (1.15-1.84) & 1.62 (1.28-2.04) for 65-74 & ≥75 years, respectively] and concomitant aspirin therapy [1.76 (1.47-2.10)] or aspirin plus 
clopidogrel/ticlopidine [1.57 (1.08-2.26)] predicted clinically relevant bleeding. 
Conclusions: Combination antithrombotic therapy increases the risk of clinically relevant bleeding in AF patients and does not reduce the risk of 
stroke. Such treatment should be avoided unless there is a clear indication for concomitant AP therapy. 
Table: Baseline characteristics predicting clinically relevant bleeding
Baseline characteristic N N event (% per year) Hazard ratio (95% CI) p-value
Age (years)
65-75
≥75
1818
1611
237 (13.0)
234 (14.5)
1.47 (1.16-1.85)
1.70 (1.35-2.15) <0.0001
Female sex 1533 207 (13.5) 1.12 (0.95-1.33) 0.19
Baseline creatinine 
clearance (ml/min)
<50
50-80
819
1990
122 (14.9)
264 (13.3)
1.49 (1.19-1.88)
1.28 (1.06-1.54) 0.0017
CHADS2 risk class
Moderate
High
1448
1248
174 (12.0)
176 (14.1)
1.02 (0.84-1.25)
1.23 (1.01-1.50) 0.095
Previous VKA use 3476 414 (11.9) 0.78 (0.65-0.93) 0.007
Concomitant aspirin usea 971 190 (19.6) 1.83 (1.54-2.18) <0.0001
Concomitant clopidogrel/
ticlopidine usea 126 32 (25.4) 2.08 (1.45-2.96) <0.0001
aSome patients took more than one antiplatelet agent (aspirin/clopidogrel/ticlopidine) during the study
